HOPHD
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, a… Read more
HOPHD (HOPHD) - Total Liabilities
Latest total liabilities as of December 2023: $3.32 Million USD
Based on the latest financial reports, HOPHD (HOPHD) has total liabilities worth $3.32 Million USD as of December 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
HOPHD - Total Liabilities Trend (2020–2023)
This chart illustrates how HOPHD's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
HOPHD Competitors by Total Liabilities
The table below lists competitors of HOPHD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bayside Corp
PINK:BYSD
|
USA | $3.22 Million |
|
Memex Inc
PINK:MENXF
|
USA | $2.05 Million |
|
AB SCIENCE (A8D.SG)
STU:A8D
|
Germany | €46.51 Million |
|
Tritium Dcfc Ltd
OTC:DCFC
|
USA | $418.83 Million |
|
AURION RES
MU:8RA
|
Germany | €3.42 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down HOPHD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.54 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HOPHD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HOPHD (2020–2023)
The table below shows the annual total liabilities of HOPHD from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $3.32 Million | -13.62% |
| 2022-12-31 | $3.85 Million | +990.88% |
| 2021-12-31 | $352.84K | -80.28% |
| 2020-12-31 | $1.79 Million | -- |